title: [Advances in the treatment of multiple sclerosis?].
abstract: The natural course of multiple sclerosis (MS) is probably more favourable than previously assumed years ago. Since the introduction of interferons in Germany, the establishment and further development of new diagnostic criteria (McDonald criteria), the causal and symptomatic treatment possibilities and initiation of therapy early in the course of the disease have led to a considerable change in the treatment of MS. MS attacks are usually treated with the intravenous administration of high-dosed steroids. When the attack symptoms do not sufficiently subside, plasmapheresis can be considered. For long-term treatment of MS, beta interferon, glatirameracetate and natalizumab are available as basic causal therapy and natalizumab and mitoxantrone are available for escalation therapy. Frequently occurring spasticity, chronic fatigue syndrome, depression, cognitive disturbances, incontinence, pain, ataxia and sexual disorders must be treated symptomatically. Overall, the outpatient treatment of MS is complex and should be carried out with close cooperation between the family doctor, neurological practices and outpatient departments specialized in treating MS.
authors.affiliation: Philipps Universität Marburg und Universitäts-klinikum Giessen. tackenbb@med.uni-marburg.de
authors.forename: B
authors.initials: B
authors.lastname: Tackenberg
authors.forename: H
authors.initials: H
authors.lastname: Himmerich
authors.forename: A
authors.initials: A
authors.lastname: Wellek
authors.forename: W H
authors.initials: WH
authors.lastname: Oertel
authors.forename: N
authors.initials: N
authors.lastname: Sommer
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007167:Immunotherapy; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D000069442:Natalizumab; D010045:Outpatients; D010956:Plasmapheresis; D011379:Prognosis; D013997:Time Factors
chemical_list: D000700:Analgesics; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D016899:Interferon-beta; D003520:Cyclophosphamide; D008942:Mitoxantrone